Bristol Myers Squibb Presents Sotyktu (deucravacitinib) Data Showing Durable Efficacy, Consistent Safety in Adults with Psoriatic Arthritis Over Two Years (Bristol-Myers Squibb Press Release) - Sep 17, 2026 - "These data are being presented at the Congress of Clinical Rheumatology - West (CCR-West) in Huntington Beach, California...Among patients who entered the OLE, Sotyktu demonstrated durable efficacy, with clinical responses continuing to improve from Week 16 through Week 52 and maintained through Week 104. Responses were robust across key clinical efficacy measures, including American College of Rheumatology (ACR) 20/50/70 and Minimal Disease Activity (MDA), both for patients who received Sotyktu continuously from the start of the Phase 3 study through the OLE and patients who switched from placebo to Sotyktu at Week 16 and continued Sotyktu through the remainder of the Phase 3 study and OLE...Among patients who received Sotyktu continuously from the beginning of the Phase 3 study through the OLE, ACR 20/50/70 response rates at Week 104 were 76.2%, 52.6% and 34.6%, respectively, based on observed analysis, and 65.3%, 44.9% and 29.4%, respectively, using nonresponder imputation (NRI)."
P3 data • Immunology • Psoriatic Arthritis
|